Lantheus (LNTH) Downgraded by BidaskClub

BidaskClub downgraded shares of Lantheus (NASDAQ:LNTH) from a strong-buy rating to a buy rating in a report released on Thursday morning, BidAskClub reports.

LNTH has been the topic of several other reports. TheStreet upgraded shares of Lantheus from a c+ rating to a b rating in a research report on Monday, March 4th. Zacks Investment Research cut shares of Lantheus from a buy rating to a hold rating in a research report on Wednesday, February 6th. Finally, ValuEngine cut shares of Lantheus from a buy rating to a hold rating in a research report on Wednesday, January 2nd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $23.33.

LNTH opened at $24.15 on Thursday. Lantheus has a 52 week low of $12.59 and a 52 week high of $26.30. The stock has a market cap of $930.93 million, a price-to-earnings ratio of 25.16, a P/E/G ratio of 1.74 and a beta of 1.59. The company has a quick ratio of 3.08, a current ratio of 3.70 and a debt-to-equity ratio of 3.71.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Tuesday, February 19th. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.09. The firm had revenue of $86.27 million for the quarter, compared to analysts’ expectations of $83.93 million. Lantheus had a net margin of 11.80% and a return on equity of 73.07%. The business’s revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.47 EPS. On average, sell-side analysts forecast that Lantheus will post 1.15 EPS for the current fiscal year.

In other news, insider Cesare Orlandi sold 3,060 shares of the company’s stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $16.56, for a total transaction of $50,673.60. Following the sale, the insider now directly owns 77,746 shares in the company, valued at approximately $1,287,473.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director A Frederick Robertson sold 3,932 shares of the stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $22.77, for a total transaction of $89,531.64. Following the completion of the sale, the director now directly owns 43,062 shares in the company, valued at $980,521.74. The disclosure for this sale can be found here. Insiders have sold a total of 75,062 shares of company stock worth $1,699,814 over the last 90 days. Corporate insiders own 2.60% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its position in Lantheus by 20.1% in the 3rd quarter. BlackRock Inc. now owns 5,579,963 shares of the medical equipment provider’s stock worth $83,419,000 after purchasing an additional 933,791 shares during the period. LSV Asset Management raised its position in Lantheus by 84.7% in the 4th quarter. LSV Asset Management now owns 1,599,532 shares of the medical equipment provider’s stock worth $25,032,000 after purchasing an additional 733,611 shares during the period. Vaughan Nelson Investment Management L.P. raised its position in Lantheus by 11.5% in the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 1,503,375 shares of the medical equipment provider’s stock worth $23,529,000 after purchasing an additional 155,600 shares during the period. Dimensional Fund Advisors LP raised its position in Lantheus by 5.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,379,017 shares of the medical equipment provider’s stock worth $21,581,000 after purchasing an additional 65,609 shares during the period. Finally, Tamarack Advisers LP raised its position in Lantheus by 0.5% in the 4th quarter. Tamarack Advisers LP now owns 975,000 shares of the medical equipment provider’s stock worth $15,259,000 after purchasing an additional 5,000 shares during the period. 93.34% of the stock is currently owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Recommended Story: Rule of 72

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.